AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
The Ahmedabad based hospital in association with Sankalp India Foundation had established the BMT unit in 2017
Arrow is the marketing partner in US
The facility combines advanced diagnostics, bone marrow transplant evaluation, prenatal awareness, and multidisciplinary support services
Hair care & quick commerce shine
The leading cancer hospital urges carrier screening to prevent thalassemia burden
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Marking World Asthma Day 2026, doctors sounded the alarm over a steady surge in respiratory illnesses
The company says the product will now be distributed exclusively through Anovo Specialty Pharmacy
Subscribe To Our Newsletter & Stay Updated
